Highlights

I think I’m more of a purist, I think OS is the definitive thing. I think it’s becoming more and more difficult to use that because the other thing that’s happened is that many, many more people go to bone marrow transplant, so you can’t do a good survival study if many of the patients get a transplant. So, you’re going to have to censor so many people that you’re not going to be able to get to the endpoint. But I would argue that there is not a correlation between response and survival; yes, they are linked sometimes, but there are notable examples even in AML where they’re not linked.

Since [the reason for magrolimab’s clinical hold] is not specified, it’s hard to say, usually this is going to be something like there’s some excess toxicities, that’s usually what the hold is, and so, the question is, what might be the excess toxicity. If it’s excess deaths then that’s not good. If it’s infection, or something like that, maybe, but I think that having a hold is not good. I think we can all agree on that, being held is not good. I think being held and not saying what the hold is for is really not good.